<DOC>
	<DOCNO>NCT02454361</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , dose-escalation study evaluate safety , tolerability pharmacokinetics single dose KBP-7072 follow oral single ascend dose administration open label food effect panel .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics KBP-7072</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , dose-escalation study evaluate safety , tolerability pharmacokinetics single dose KBP-7072 follow oral single ascend dose administration open label food effect panel . Part 1 : A total 40 subject evaluate 30 subject randomize receive active drug 10 subject randomize receive placebo double-blind fashion ( eight subject dose cohort , six subject randomize active drug two subject randomize placebo ) . 5 dose level evaluate . Extensive PK sampling collect dose ( pre-dose ( within 30 min prior dose ) 0.5 , 1 , 2 , 4 , 6 , 10 , 12 , 18 , 24 , 36 , 48 , 72 , 96 , 120 , 144 , 168 , 192 , 216 240 hr post-dose ) . Part 2 : A separate panel 6 subject receive single dose KBP-7072 fed condition . The dose test Part 2 determine base safety , tolerability PK data available Part 1 . Extensive PK sampling collect dose ( pre-dose ( within 45 min prior dose ) 0.5 , 1 , 2 , 4 , 6 , 10 , 12 , 18 , 24 , 36 , 48 , 72 , 96 , 120 , 144 , 168 , 192 , 216 240 hr post-dose ) . Safety assessment include monitor adverse event ( AEs ) , vital sign ( blood pressure , pulse rate , respiratory rate oral temperature ) , clinical laboratory finding , 12-lead electrocardiogram ( ECGs ) , physical examination finding .</detailed_description>
	<criteria>male surgically sterile postmenopausal female age 1845 year body mass index ( BMI ) 19 ≤ BMI ≤ 30 kg/m2 , significant medical history normal renal function good general health Clinically significant history gastrointestinal , cardiovascular , musculoskeletal , endocrine , hematologic , psychiatric , renal , hepatic , pulmonary , neurologic , immunologic , lipid metabolism disorder , drug hypersensitivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>KBP-7072</keyword>
</DOC>